header image left image Laboratory of Integrative Cancer Immunology
  Research Projects  
  HalioDx Website  
Immuno-Oncology Diagnostic company, Co-founder Dr. Jérôme Galon

HalioDx vision is to create a leader in Immuno-Oncology diagnostics, the emerging segment of the cancer molecular diagnostic market (MDx).

HalioDx plan is to develop a unique portfolio of MDx -IVDs solutions dedicated to Immuno-Oncology.

Dr. Jérôme Galon is a co-founder of HalioDx. The co-founders are experienced executives with extensive track records in the Diagnostic Industry, Pharma & BioTech Management.

The company is a spin-off of Qiagen Marseille, a subsidiary of Qiagen NV, previously known as Ipsogen, leader in developing MDx-IVDs for blood-based cancers.

Dr. Jérôme Galon
Co-founder of HalioDx
Immuno-Oncology Diagnostic company, Co-founder Dr. Jérôme Galon

HalioDx has a unique Immuno-Oncology (I-O) technology. HalioDx licenced a comprehensive patent portfolio from Dr. Jérôme Galon & colleagues (INSERM UMRS1138), covering clinical use of I-O biomarkers, ImmunoscoreTM concept (IHC) & gene expression signatures (MDx), Assays & biomarkers correlated to prognosis and/or response to cancer therapeutics, with patents granted in US, EU and Japan.

HalioDx has State of the art R&D, manufacturing facilities and expertise, with IVD compliant Quality System / ISO 13 485/ GMP, Fully qualified and trained staff (140+ FTEs), and compliant R&D & manufacturing facilities. HalioDx Inc. has been established in Richmond, VA, USA in Dec 2018. Two HalioDx CLIA certified laboratories are available for testing, in Marseille France and in Richmond USA.